These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29802901)

  • 21. High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Czerw T; Labopin M; Schmid C; Cornelissen JJ; Chevallier P; Blaise D; Kuball J; Vigouroux S; Garban F; Lioure B; Fegueux N; Clement L; Sandstedt A; Maertens J; Guillerm G; Bordessoule D; Mohty M; Nagler A
    Oncotarget; 2016 May; 7(19):27255-66. PubMed ID: 27036034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory T cells promote alloengraftment in a model of late-gestation in utero hematopoietic cell transplantation.
    Riley JS; McClain LE; Stratigis JD; Coons BE; Ahn NJ; Li H; Loukogeorgakis SP; Fachin CG; Dias AIBS; Flake AW; Peranteau WH
    Blood Adv; 2020 Mar; 4(6):1102-1114. PubMed ID: 32203584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?
    Zeiser R; Blazar BR
    Blood; 2016 Jun; 127(25):3117-26. PubMed ID: 26994149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Canine Model of Chronic Graft-versus-Host Disease.
    Graves SS; Rezvani A; Sale G; Stone D; Parker M; Rosinski S; Spector M; Swearingen B; Kean L; Storb R
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):420-427. PubMed ID: 28013013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Intravenous Route of Injection Optimizes Engraftment and Survival in the Murine Model of In Utero Hematopoietic Cell Transplantation.
    Boelig MM; Kim AG; Stratigis JD; McClain LE; Li H; Flake AW; Peranteau WH
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):991-999. PubMed ID: 26797401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation.
    Ashizuka S; Peranteau WH; Hayashi S; Flake AW
    Exp Hematol; 2006 Mar; 34(3):359-68. PubMed ID: 16543070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In utero stem cell transplantation.
    Flake AW
    Best Pract Res Clin Obstet Gynaecol; 2004 Dec; 18(6):941-58. PubMed ID: 15582548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by α4β1/7 inhibition.
    Kim AG; Vrecenak JD; Boelig MM; Eissenberg L; Rettig MP; Riley JS; Holt MS; Conner MA; Loukogeorgakis SP; Li H; DiPersio JF; Flake AW; Peranteau WH
    Blood; 2016 Nov; 128(20):2457-2461. PubMed ID: 27650329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Strategy of Acute Graft-vs-Host Disease: Investigation of a Reduced Dose of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation.
    Sun Y; Wei C; Cao C; Tan X; Zeng H; Luo Y; Chen L
    Transplant Proc; 2019 Apr; 51(3):890-895. PubMed ID: 30979481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
    Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L
    Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of T-cell antibodies for donor dosaging in a canine model of in utero hematopoietic stem cell transplantation.
    Petersen SM; Gendelman M; Murphy KM; Torbenson M; Jones RJ; Althaus JE; Stetten G; Bird C; Blakemore KJ
    Fetal Diagn Ther; 2007; 22(3):175-9. PubMed ID: 17228153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In utero hematopoietic cell transplantation: induction of donor specific immune tolerance and postnatal transplants.
    Peranteau WH
    Front Pharmacol; 2014; 5():251. PubMed ID: 25429269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.